Post-Market Clinical Monitoring Reports for Class 3 and Implantable Devices

1. Key takeaways

Manufacturers of class 3 devices and implantable class 2b devices are under an obligation to prepare and submit a post-market clinical monitoring report (ПКМ). The report is formally listed as one of the data sources of the safety monitoring system under Order No. 540n. Where the report is not submitted on time, the consequence follows subparagraph “i” of p. 137 of Government Decision No. 1684: the registration is first suspended for 30 working days, and if the violation is not eliminated within that period, the registration is cancelled. The obligation therefore carries a direct and severe consequence for the certificate itself, not merely an administrative reprimand.

Two points should be fixed in the planning of any affected portfolio. First, the obligation is determined by the risk class and the implantable attribute of the device, which are matters of written determination rather than judgement by experience — a product that straddles categories must be assessed against the classification rules and documented. Second, the suspension period of thirty working days is a remediation window, not a buffer: the report must be submitted and the violation eliminated inside it, so a company that waits for a suspension notice before starting to compile data has in practice already lost the window.

2. Legal basis

The obligation is created by the interplay of two instruments — the registration rules define the consequence, and the safety monitoring order defines the status of the report as a data source. The classification instruments determine which products are caught. All are summarised below.

3. Expert insights

Insight 1: the obligation arises from the intersection of two documents. Decision No. 1684 defines the consequence and Order No. 540n defines the status — the ПКМ report is listed as one of the four data sources of safety monitoring. Together the two documents form a single obligation chain: the manufacturer must produce the report, the report feeds the monitoring system, and failure to produce it triggers the registration consequence. Companies that read only the registration rules see a sanction; companies that read only the monitoring order see a data flow. The compliance duty is only visible when both are read together.

Insight 2: the implantable determination is the trigger condition. The Union classification rules define an implantable device as one intended to remain in place after surgery for more than 30 days, and partly absorbable or degradable devices also fall within the definition. Whether a product triggers ПКМ must therefore be decided in writing against Decision No. 173 and the nomenclature classification, not by analogy with other markets or by habit. Borderline products — long-term catheters, degradable scaffolds, meshes — deserve a documented determination, because the determination is exactly what an inspector will ask to see first.

Insight 3: the value of the report lies in long-term data. ПКМ data can expose design weaknesses long before they accumulate into adverse events. Companies that treat the report as a pure compliance cost usually end up paying more in event handling; when the data is connected into a closed loop with design changes and post-market investigation, it reduces the cost of subsequent adverse event handling instead. The report should be planned as an output of the quality system rather than as a document produced once a year for the regulator.

4. Practical recommendations

A repeatable annual cycle is the difference between a report that evidences monitoring and a report that merely documents delay.

1. Establish an annual ПКМ calendar that fixes the data cut-off points, the drafting cycle and the internal review milestones, and publish it to every function that contributes data.
2. Connect ПКМ results to the management review of the quality management system, so that findings translate into design, labelling or IFU actions rather than remaining in a regulatory document.
3. Prepare a remediation plan for the 30 working day suspension window: as soon as a suspension notice arrives, launch the corrective submission immediately, on a working day schedule agreed in advance with the data owners.
4. Document the implantable determination for each product against Decision No. 173 and Order No. 4n, and keep the determination in the regulatory file for inspector review.

5. Verification checklist

The items below evidence both the scope determination and the operating cycle.

• □ The products required to submit ПКМ reports (class 3, class 2b implantable) are listed
• □ The implantable attribute is determined in writing against Decision No. 173 (remaining in place for more than 30 days)
• □ The annual calendar contains data cut-off points and the drafting cycle
• □ ПКМ results feed into the management review of the QMS
• □ A remediation plan for the 30 working day suspension window has been prepared
• □ The responsible person for submission and the internal review chain are named

Regulatory information verified as of 29 October 2026.

GRZAN assists manufacturers of class 3 and implantable class 2b devices in Russia with post-market clinical monitoring, from annual ПКМ calendars and data collection workflows to remediation submissions within suspension windows, alongside vigilance, recall and inspection readiness support. To discuss your ПКМ programme, contact us at info@grzanglobal.com.